Bortezomib-induced severe hepatitis in multiple myeloma: a case report.
Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.
Rosiñol
Laura
L
Hematology Department, Institut d'Investigacions Biomèdiques August Pi I Sunyer, Hospital Clínic, Barcelona, Spain.
Montoto
Silvia
S
Cibeira
Maria Teresa
MT
Bladé
Joan
J
D000368:Aged; D000410:Alanine Transaminase / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001219:Aspartate Aminotransferases / Q000097:blood; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D056487:Chemical and Drug Induced Liver Injury, Chronic / Q000201:enzymology / Q000209:etiology*; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D008297:Male; D009101:Multiple Myeloma / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000009:adverse effects*; D011719:Pyrazines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D011480:Protease Inhibitors; D011719:Pyrazines; D000069286:Bortezomib; D007770:L-Lactate Dehydrogenase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase